US firm invests $250M to address employee obesity
The article reviews how an American company spends over $250 million annually on treating employee obesity with GLP-1 class medications. It considers this an investment in workforce health, leading to clear positive effects on employees. The cost of these medications accounts for about 13% of the company's total annual healthcare expenditure. There is growing demand for obesity and diabetes drugs such as Ozempic and Wegovy, which can cost thousands of dollars annually per patient. Additionally, data indicates that employer coverage for these medications increased to 36% in 2025 and accounted for 11.4% of health claims in 2026, making them a crucial factor in treatment decisions and insurance coverage.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)